Key terms
About IMAB
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMAB news
Apr 15
9:03pm ET
I-Mab Announces CMO Transition, Interim Successor Named
Apr 12
6:08am ET
I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline
Apr 02
5:59pm ET
I-Mab Finalizes Divestiture and Resolves Obligations
Apr 01
9:57am ET
I-Mab Announces Major Leadership Reshuffle
Mar 18
6:45am ET
I-Mab price target lowered to $10 from $15 at Piper Sandler
Mar 18
6:20am ET
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
Mar 18
6:06am ET
I-Mab price target lowered to $8 from $18 at H.C. Wainwright
Feb 12
8:18am ET
I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline
Feb 08
3:10pm ET
Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)
Feb 07
6:22am ET
I-Mab to divest assets, business operations in China fo $80M
No recent press releases are available for IMAB
IMAB Financials
Key terms
Ad Feedback
IMAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
